Nasus Pharma Ltd
nasuspharma.comWhat Do They Do?
Develops intranasal powder medicines for emergency conditions, including epinephrine for severe allergic reactions and naloxone for opioid overdose.
20-F for FY2025, filed Mar 25, 2026We are a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical…View ↗
Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective…View ↗
Our platform technology can also be incorporated into other products as it has been tested with additional preclinical and in-vitro…View ↗
How Do They Make Money?
$1.2B
-
20-F for FY2025, filed Mar 25, 2026
$1.2B ↗
Do Revenues Turn Into Profits?
No. It lost $5.9M in FY2025.
20-F for FY2025, filed Mar 25, 2026
−$4.9MView ↗
20-F for FY2025, filed Mar 25, 2026
−$5.9MView ↗
20-F for FY2025, filed Mar 25, 2026
−$4.9MView ↗
Who Do They Compete With?
Competes with Emergent BioSolutions, Teva, Sandoz, Summit Biosciences, Hikma Pharmaceuticals, ARS Pharmaceuticals, Bryn Pharma, Orexo, and Aquestive Therapeutics
20-F for FY2025, filed Mar 25, 2026Since Emergent BioSolutions Inc.’s acquisition of Narcan in 2017, its sales of Narcan consistently beat the market expectation as well as…View ↗
Loading...
